Long-term safety registry for Increlex in children
Part of Hormones & metabolism clinical trials.
This study is a registry that follows children and teens with severe IGF-1 deficiency who use Increlex (or specific GH gene deletion situations) to better track long-term safety and effectiveness. You would likely join if your child is already starting or planning Increlex and is not in other growth-related drug trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have severe primary IGF-1 deficiency that fits the Increlex label (or GH gene deletion in the US case).
- Your child is starting Increlex, planning to start it, or currently taking it (per the approved label where you live).
- A parent or legal guardian must sign consent before any registry activities begin; your child should give assent when appropriate.
- Your child must NOT be currently in an Increlex clinical trial.
- Your child must NOT be currently in another clinical trial for growth (growth retardation).
- Your child must not have certain reasons to avoid Increlex (like allergy to it, known or suspected tumors/cancer, or growth plate/epiphysis already closed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows participants who previously received the RGX-111 treatment to monitor their health over time. It helps researchers understand the long-term effects and safety of the therapy.
This early-phase study tests inlexisertib (a targeted cancer drug) combined with other anticancer treatments in adults with advanced GIST. It is mainly looking for safety and the best way to dose, and it may help tumors that have certain KIT or PDGFRA gene changes.
This trial studies how well infigratinib works and remains safe for children with achondroplasia. It includes children who already took infigratinib in a prior QED study, and some who are starting treatment for the first time.
This study tests a new injectable growth hormone treatment for adults whose bodies don't produce enough growth hormone naturally. Researchers will measure how safe it is, how your body processes it, and whether it helps you feel better and function more normally.
This trial tests an oral medication called GS3-007a for children who have not yet reached puberty and have growth hormone deficiency. The goal is to see if it helps them grow taller.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
Hear when a new IGF1 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.